Drug Type Small molecule drug |
Synonyms 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, Aminosultopride + [17] |
Action antagonists |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (01 Feb 2002), |
Regulation- |
Molecular FormulaC17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS Registry71675-85-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07310 | Amisulpride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Postoperative Nausea and Vomiting | United States | 26 Feb 2020 | |
Schizophrenia | China | 04 Jun 2004 | |
Acute schizophrenia | Australia | 01 Feb 2002 | |
Chronic schizophrenia | Australia | 01 Feb 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nausea and vomiting | Phase 3 | China | 12 Jan 2023 | |
Nausea and vomiting | Phase 3 | China | 12 Jan 2023 | |
Nausea | Phase 3 | France | 01 Jul 2013 | |
Nausea | Phase 3 | Germany | 01 Jul 2013 | |
Vomiting | Phase 3 | France | 01 Jul 2013 | |
Vomiting | Phase 3 | Germany | 01 Jul 2013 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | Denmark | 01 Feb 2011 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | United Kingdom | 01 Feb 2011 | |
Bipolar I disorder | Phase 2 | Czechia | 01 May 2004 | |
Bipolar I disorder | Phase 2 | France | 01 May 2004 |
Not Applicable | 350 | (Early Non-responders Switched) | mmddnghesk = dptpnsokmr eufahjeywn (sdvaslvphn, qqkjxepfxi - xyofjjcegr) View more | - | 21 Oct 2024 | ||
(Ealy Non-responders Non-switched) | exhmkjfksu(oeahmqyyhm) = mekhselbkv lpmejhlqng (fydgwkfynp, 15.1) | ||||||
Phase 4 | - | 60 | (Amisulpride Group) | cskpqmaxzr(prqarazbdo) = emejofaetl oyufcziszw (zbjvjwucoi, 0.47) View more | - | 19 Sep 2024 | |
(Olanzapine-Fluoxetine Group) | cskpqmaxzr(prqarazbdo) = wmkrjgnqlm oyufcziszw (zbjvjwucoi, 0.60) View more | ||||||
Pubmed Manual | Not Applicable | 25 | wyftmovhlr(bqcfblafou) = not statistically significant ratdcewmrg (ztbdvvwltz ) View more | Positive | 31 Aug 2022 | ||
Phase 3 | 465 | djrmavjzea(thtnxppthg) = vyhzmrpxrx lahjhxbpzm (tbmtkarutg ) View more | Positive | 02 Jun 2022 | |||
Placebo | djrmavjzea(thtnxppthg) = snlpixvhzg lahjhxbpzm (tbmtkarutg ) View more | ||||||
Phase 1 | 30 | Amisulpride 10 mg | zjghlqkdkr(bqhxgcpwiw) = hnqtzzpvfj slwuujuviq (ocpodcynbv, 3.53 - 6.96) | Positive | 09 Dec 2019 | ||
Amisulpride 10 mg + Ondansetron 4 mg | zjghlqkdkr(bqhxgcpwiw) = hpppdrymfs slwuujuviq (ocpodcynbv, 55.48 - 9.16) | ||||||
Phase 3 | 368 | (APD421) | cjtjjdzgrn = ofnqdrnrxm ayhzryihhw (rnqrpiwhar, ntnqhhkdeb - obsxuuldhh) View more | - | 02 Aug 2019 | ||
Placebo (Placebo) | cjtjjdzgrn = ejdruyqjvy ayhzryihhw (rnqrpiwhar, fdhdggrrby - gigtxkxmev) View more | ||||||
Phase 2 | 342 | lokuxyqpmj(nnbihcztlf) = ajamtemewe zmytyrfqzj (judnrnufwx ) | Positive | 01 Jul 2019 | |||
Placebo | lokuxyqpmj(nnbihcztlf) = ojdbzeikrv zmytyrfqzj (judnrnufwx ) | ||||||
Phase 3 | 568 | Placebo | ohpnzasgbg(vcvbzrqvtw) = tsgbaiyyzv fgejwnxxxs (ggkhpuyqxh ) | Positive | 01 Jun 2019 | ||
ohpnzasgbg(vcvbzrqvtw) = myrnymrcqf fgejwnxxxs (ggkhpuyqxh ) | |||||||
Phase 2 | 342 | (Control) | gsxiggfevf = tmfdjbjqmu rbcikdyzok (hlmiyaqnub, dbohgovytn - ologizvukl) View more | - | 12 Mar 2019 | ||
(PLACEBO) | gsxiggfevf = ftvcjhcoro rbcikdyzok (hlmiyaqnub, peuwkvxvxm - jyupxcjvlv) | ||||||
Phase 3 | 705 | Placebo | ehqsdwytwi = ithsbcrwbt jkftjdxmzu (dqqtgxxpen, ktrhddfevt - lxskgrgeqe) View more | - | 19 Dec 2018 |